D2/5-HT2 antagonists (Burroughs Wellcome)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug NameD2/5-HT2 antagonists (Burroughs Wellcome)
Drug Alias Namecyclic benzamides (Burroughs Wellcome)antipsychotics (Burroughs Wellcome)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D2 receptor antagonistsSerotonin 2 (5-HT2) receptor antagonists
TargetsSerotonin 2 (5-HT2) receptorDopamine D2 receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBurroughs Wellcome
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxo Group Ltd
Active IndicationsN/A
Inactive IndicationsSchizophrenia

Other Information

ATC CodeN/A
Related LinksN/A